Every 8-K that Bone Biologics Corp (BBLG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBLG filings page.
Bone Biologics Corp (BBLG) reports a Nasdaq bid‑price deficiency notice after its common stock closed below $1 per share for the last 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, until March 9, 2027, to regain compliance by achieving a closing bid of at least $1 per share for a minimum of 10 consecutive business days.
If compliance is not regained by March 9, 2027, the company may qualify for a second 180‑day period if it meets certain other Nasdaq Capital Market standards and notifies Nasdaq of its intent to cure the deficiency. Failure to comply could lead to delisting, subject to an appeal. The company states it will monitor its share price and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting, which its board may use to attempt to increase the share price and restore compliance. The notice has no immediate effect on the current Nasdaq listing.
Bone Biologics Corporation provided a mid-2026 shareholder update covering financing, clinical progress and manufacturing readiness for NB1, its rhNELL-1-based bone graft candidate for spinal fusion. In July 2026, the company completed a private placement with a single healthcare-focused institutional investor, generating approximately $3.0 million in gross proceeds before fees.
The financing included Series F and Series G warrants that could deliver up to approximately $6.0 million in additional gross proceeds if fully exercised for cash. Bone Biologics believes this capital extends its operating runway through Q2 2027 to support clinical trials, patent portfolio work and general operations. The company continues its first-in-human NB1 pilot study and expects to complete enrollment by year-end 2026. In May 2026, the validated shelf life of the rhNELL-1 protein was extended to 29 months, supporting manufacturing and supply-chain planning.
Bone Biologics Corporation postponed its 2026 annual meeting of stockholders, originally set for August 11, 2026, to September 28, 2026 at 11:30 a.m. Eastern Time at its Burlington, Massachusetts offices.
The Board plans to file a Definitive Proxy Statement on Schedule 14A including an additional proposal and concluded more time is needed for stockholders to review materials. The new record date is August 6, 2026, and the deadline for stockholder nominations or other business is July 26, 2026.
Bone Biologics Corporation entered into a private placement with a single institutional investor, raising gross proceeds of approximately $3.0 million and net proceeds of about $2.7 million. The deal includes 2,112,677 pre-funded warrants and accompanying Series F and Series G warrants to purchase up to a total of 6,338,031 shares of common stock at $1.42 per share, subject to ownership caps of 4.99% or 9.99%.
The Series F warrants have a five-year term and the Series G warrants have an 18‑month term, each starting from the later of stockholder approval and effectiveness of a resale registration statement. If all investor warrants are exercised for cash, the Company could receive additional gross proceeds of about $6.0 million. Placement agent H.C. Wainwright & Co. received cash fees, expense reimbursements, and warrants to purchase 126,761 shares. The Company plans to use proceeds for clinical trials, patent portfolio maintenance, working capital, and general corporate purposes.
Bone Biologics Corporation is updating its at-the-market equity offering program to permit sales of up to $1,064,000 of common stock through H.C. Wainwright & Co. as sales agent under an existing sales agreement. These potential sales are covered by a prospectus supplement dated March 13, 2026, tied to the company’s effective Form S-3 shelf registration statement. The company previously sold approximately $1.7 million of common stock under the same sales agreement using an earlier shelf registration, which is no longer effective. A legal opinion regarding the validity of the shares covered by the new prospectus supplement is filed as an exhibit.
Bone Biologics Corporation filed a current report to furnish, rather than file, a press release dated January 8, 2026. The press release summarizes the company’s corporate, scientific and operational milestones achieved during 2025 and outlines its strategic outlook for 2026. This information is provided under Item 7.01 of the Exchange Act and is expressly not deemed filed or subject to Section 18 liabilities, nor incorporated by reference into other Securities Act or Exchange Act filings. The press release is included as Exhibit 99.1 to the report.